TEVA Q3 2018 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.5B-19.3% YoY

Gross Profit

$2.0B44.6% margin

Operating Income

$16M0.4% margin

Net Income

-$208M-4.6% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

-3.7%

Cash Flow

Operating Cash Flow

$421M

Free Cash Flow

$282M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$65.1B

Total Liabilities

$45.9B

Stockholders' Equity

$17.7B

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.5B	$5.6B	-19.3%
Gross Profit	$2.0B	$2.6B	-23.5%
Operating Income	$16M	$378M	-95.8%
Net Income	-$208M	$530M	-139.2%

Revenue Segments

International Markets

$498M100%

Geographic Segments

North America

$1.9B61%

Europe

$1.2B39%